China Passes Landmark Medical Security Law
China's first dedicated Medical Security Law establishes a legal framework for universal healthcare, covering insurance and anti-fraud measures.
Tag
14 articles
China's first dedicated Medical Security Law establishes a legal framework for universal healthcare, covering insurance and anti-fraud measures.
China recovered 118.2 billion yuan in medical insurance funds during the 14th Five-Year Plan period, using AI-powered monitoring and stricter enforcement.
China's medical insurance spending surpassed 3 trillion yuan in 2025 as income growth outpaced expenditure, signaling improved fund sustainability.
China reports 525.8 billion yuan medical insurance surplus while top oncologist Xu Ruihua faces academic fraud allegations in a paper mill scandal.
China's NHSA announces 601 drugs passed formal review for the 2026 medical insurance catalog, with a 91% pass rate and expanded access for patients.
China's NHSA launches a 'Find Medicine' digital feature, helping insured patients locate medications covered by insurance nationwide.
China's NHSA launches a nationwide drug price comparison mini-program across all 31 provinces, helping patients compare prices and reduce medication costs.
China launches cross-province medical insurance account sharing, allowing 300M+ migrant workers to share funds with family nationwide.
China's NHSA reveals four new pharmacy fraud cases in Qinghai and Guangxi, using big data to detect returned drug sales and substitution schemes.
China launches cross-province medical insurance personal account sharing, allowing funds to be used by close relatives nationwide.
China's NHSA launches 2026 dual catalog adjustment for medical and commercial insurance, introducing pre-application mechanisms and expanded eligibility.
China's NHSA will release the first national Basic Medical Insurance Service Directory in Q4 2026, standardizing coverage for 11 categories.
China's NHSA exposes six pharmacy cases involving medical insurance fraud, including drug swapping, empty swiping, and reselling returned drugs.
China's medical insurance fund spent 61.26 billion yuan on special case reviews in 2025, covering 2.07 million complex medical cases under DRG reform.